N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Names and Identifiers

Name	Methotrexate
Synonyms	Mtx Antifolan 4-Amino-1 Amethopterin Methotrexate L-Methotrexate (+)-Amethopterin Methotrexat-Ebewe Methylaminopterin Methylaminopterine L-(+)-Amethopterin Methylpteroylglutamate 4-Amino-4-Deoxy-N(Sup10 METHOTREXATEFORINJECTION Methylpteroylglutamic Acid 4-Amino-10-Methylfolic Acid 4-Amino-N10-methylfolic acid (+)-4-Amino-10-Methylfolic Acid 4-Amino-N 10-Methylpteroyl-L-Glutamic Acid 4-Amino-4-Deoxy-N(Sup10)Methylpteroylglutamic Acid N-[4-[[(2,4-Diamino-6-Pteridinyl)Methyl]Methylamino]Benzoyl]-L-Glutamic Acid N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid METHOTREXATE(N-(4-(((2,4-DIAMINO-6-PTERIDINYL)METHYLAMINO)BENZOYL)-L-GLUTAMICACID) L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]- (9CI) Glutamic acid, N-[p-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-, L-(+)- (8CI) sodium 4-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]am ino]-5-hydroxy-5-oxo-pentanoate
CAS	59-05-2
EINECS	200-413-8
InChI	InChI=1/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m1/s1
InChIKey	FBOZXECLQNJBKD-ZDUSSCGKSA-N

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Physico-chemical Properties

Molecular Formula	C20H22N8O5
Molar Mass	454.45
Density	1.4080 (rough estimate)
Melting Point	195°C
Boling Point	561.26°C (rough estimate)
Specific Rotation(α)	+17～+24°(D/20℃)(c=1,Na2CO3 soln.)(calculated on the dehydrous basis)
Flash Point	11℃
Water Solubility	Insoluble. <0.1 g/100 mL at 19 ºC
Solubility	Easily soluble in dilute alkali, acid or alkali metal carbonate solution, slightly soluble in dilute hydrochloric acid, almost insoluble in water, ethanol, chloroform, ether.
Appearance	Yellow crystalline powder
Merck	14,5985
BRN	70669
pKa	pKa 3.04/4.99(H2O,t =25,I=0.0025) (Uncertain)
Storage Condition	Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
Stability	Stable, but light sensitive and hygroscopic. Incompatible with strong acids, strong oxidizing agents. Store at -15C or below.
Sensitive	Light Sensitive & Hygroscopic
Refractive Index	1.6910 (estimate)
MDL	MFCD00064370
Physical and Chemical Properties	Orange-yellow crystalline powder. Melting point 185-204 °c. Soluble in dilute alkali, acid or alkali metal carbonate solution, slightly soluble in dilute hydrochloric acid, almost insoluble in water, ethanol, chloroform, ether.
Use	Antineoplastic agents for acute leukemia, choriocarcinoma, malignant mole and psoriasis

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Risk and Safety

Risk Codes	R61 - May cause harm to the unborn child R25 - Toxic if swallowed R36/38 - Irritating to eyes and skin. R46 - May cause heritable genetic damage R39/23/24/25 - R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed. R11 - Highly Flammable
Safety Description	S53 - Avoid exposure - obtain special instructions before use. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37 - Wear suitable protective clothing and gloves. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S36 - Wear suitable protective clothing. S16 - Keep away from sources of ignition.
UN IDs	UN 2811 6.1/PG 3
WGK Germany	3
RTECS	MA1225000
FLUKA BRAND F CODES	3-8-10
TSCA	Yes
HS Code	29335995
Hazard Class	6.1(b)
Packing Group	III
Toxicity	LD50 oral in rat: 135mg/kg

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Reference

Reference

1. Wang Jingxia, Liu Chunfang, Li Yiqun, etc. Inhibitory effect of Tripterygium wilfordii polyglycoside on angiogenesis in experimental rheumatoid arthritis. Chinese Journal of Traditional Chinese Medicine.
2. Liu Chunfang, Wang Jingxia, He Lianhua, etc. Effect of Fengshi qutong capsule on angiogenesis of synovium in rats with collagen-induced arthritis [J]. Chinese Journal of Traditional Chinese Medicine, 2019, 044(007):1457-1463.
3. Wang Jingxia, Liu Chunfang, He Lianhua, et al. Effect of Fengshi qutong capsule on collagen-induced arthritis in rats [J]. Chinese Journal of Experimental prescriptions, 2019, 25(02):89-95.
4. Liu Chunfang, He Lianhua, Wang Jingxia, et al. Effect of Fengshi qutong capsule on Akt and MAPK signaling pathway in rheumatoid arthritis synovium [J]. Chinese Journal of Experimental prescriptions, 2019, 25(13):43-48.
5. Duan Ziyu, Li Jianguo, Chen Jing, Liu Hongwei, Li Lina, Zhou Wu, Zhang Shoumin. Effect of Liangxue Xiaoyin granules on axis miR-155/SOCS1 in transgenic mice model of psoriasis [J]. Tianjin Medical Journal, 2020,48(11):1045-1049.
6. Ren Zeyu, Jiang Hong, Xu Yan, Shi Yongfang. Preparation and in vitro release of methotrexate loaded PLGA microspheres [J]. Journal of Shihezi University (Natural Science Edition),2020,38(06):767-772.
7. Li Bing-Tong. Effect and mechanism of iguratimod on citrullination of peripheral blood leukocytes in patients with rheumatoid arthritis [J]. Jilin University, 2020.
8. Wang, Kejia, Chunhong Xie, and Daorong Chen. "Flap endonuclease 1 is a promising candidate biomarker in gastric cancer and is involved in cell proliferation and apoptosis." International journal of molecular medicine 33.5 (2014): 1268-1274. https://doi.org
9. Mu, Y. R. , et al. "Acetazolamide ameliorates the severity of collagen-induced arthritis in rats: Involvement of inducing synovial apoptosis and inhibiting Wnt/β-catenin pathway ." International Immunopharmacology 90(2021):107214.
10. Li, Xiangyu, et al. "Folate receptor-targeting mesoporous silica-coated gold nanorod nanoparticles for the synergistic photothermal therapy and chemotherapy of rheumatoid arthritis." RSC Advances 11.6 (2021): 3567-3574.https://doi.org/10.1039/D0RA08689D
11. [IF=4.471] Jinlong Zhao et al."Multifunctional folate receptor-targeting and pH-responsive nanocarriers loaded with methotrexate for treatment of rheumatoid arthritis."Int J Nanomed. 2017; 12: 6735-6746
12. [IF=4.421] Fei Hao et al."Targeted Co-Delivery of siRNA and Methotrexate for Tumor Therapy via Mixed Micelles."Pharmaceutics. 2019 Feb;11(2):92
13. [IF=4.101] Kejia Wang et al."Flap endonuclease 1 is a promising candidate biomarker in gastric cancer and is involved in cell proliferation and apoptosis."Int J Mol Med. 2014 May;33(5):1268-1274
14. [IF=3.329] Chengcheng Zou et al."Functional analysis of miR-181a and Fas involved in hepatitis B virus-related hepatocellular carcinoma pathogenesis."Exp Cell Res. 2015 Feb;331:352
15. [IF=2.69] Juan Wu et al."Facile synthesis of magnetic-/pH-responsive hydrogel beads based on Fe3O4 nanoparticles and chitosan hydrogel as MTX carriers for controlled drug release."J Biomat Sci-Polym E. 2016;27(15):1553-1568
16. [IF=2.496] Jiang Wei et al."Synthesis and characterization of magnetic mesoporous core-shell nanocomposites for targeted drug delivery applications."J Porous Mat. 2017 Feb;24(1):257-265
17. [IF=7.727] Lina Guo et al."Rational design of metal-organic frameworks to deliver methotrexate for targeted rheumatoid arthritis therapy."J Control Release. 2021 Feb;330:119
18. [IF=5.455] He Lianhua et al."Shikonin attenuates rheumatoid arthritis by targeting SOCS1/JAK/STAT signaling pathway of fibroblast like synoviocytes."Chin Med-Uk. 2021 Dec;16(1):1-15
19. [IF=5.34] Li Cai et al."7-Hydroxycoumarin mitigates the severity of collagen-induced arthritis in rats by inhibiting proliferation and inducing apoptosis of fibroblast-like synoviocytes via suppression of Wnt/β-catenin signaling pathway."Phytomedicine. 2022 Jan;94:
20. [IF=3.943] Yu-rong Mu et al."Acetazolamide ameliorates the severity of collagen-induced arthritis in rats: Involvement of inducing synovial apoptosis and inhibiting Wnt/β-catenin pathway."Int Immunopharmacol. 2021 Jan;90:107214
21. [IF=3.361] Xiangyu Li et al."Folate receptor-targeting mesoporous silica-coated gold nanorod nanoparticles for the synergistic photothermal therapy and chemotherapy of rheumatoid arthritis."Rsc Adv. 2021 Jan;11(6):3567-3574
22. [IF=2.589] Shenghui Zhong et al."Hyaluronic Acid-Coated MTX-PEI Nanoparticles for Targeted Rheumatoid Arthritis Therapy."Crystals. 2021 Apr;11(4):321
23. [IF=4.932] Bo Meng et al."AMSP-30 m as a novel HIF-1α inhibitor attenuates the development and severity of adjuvant-induced arthritis in rats: Impacts on synovial apoptosis, synovial angiogenesis and sonic hedgehog signaling pathway."Int Immunopharmacol. 2022 Feb;10
24. [IF=3.846] Shichao Wu et al."Methotrexate and 10-hydroxycamptothecine loaded pullulan nanoparticles with the targeting property for efficient cancer therapy."MATERIALS TECHNOLOGY

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Standard

Authoritative Data Verified Data

This product is a mixture of 4-amino -10-methyl folic acid and structural analogs, the main component is L-( + )-N-[4-[(2, 4-diamino-6-pteridinyl) methyl] methylamino] benzoyl] glutamic acid. The content of C20H22N305 shall be between 98.0% and 102.0% based on the anhydrous content.

Last Update：2024-01-02 23:10:35

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Trait

Authoritative Data Verified Data

This product is orange-yellow crystalline powder.
This product is almost insoluble in water, ethanol, chloroform or ether; Soluble in dilute alkaline solution, dissolved in dilute hydrochloric acid.

specific rotation

take this product, precision weighing, add 0.05mol/L sodium carbonate solution to dissolve and quantitatively dilute to make a solution containing about 10 mg per 1 ml, the specific rotation is 19 ° to 24 ° as determined by law using a 2dm measuring tube (General rule 0621).

Last Update：2022-01-01 11:38:09

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Introduction

Folic acid antagonist, dihydroxyfolate reductase (dihydrofolate reductase) inhibitor.

Last Update：2022-10-16 17:26:42

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Differential diagnosis

Authoritative Data Verified Data

take about 5mg of this product, add 1 ml of 0.5% ammonium carbonate solution to dissolve, dilute with hydrochloric acid solution (9- 1000) to make a solution containing 10ug per lml, as determined by UV-Vis spectrophotometry (General rule 0401), there is a maximum absorption at wavelengths of 244nm and 306nm and a minimum absorption at wavelengths of 234nm and 262nm.
The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 108).

Last Update：2022-01-01 11:38:09

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Exam

Authoritative Data Verified Data

(R)-methotrexate

take this product, add mobile phase to dissolve and dilute to make a solution containing about 0.2mg per 1ml as a test solution; Take 1ml for precision measurement and put it in a 100ml measuring flask, dilute to the scale with the mobile phase, shake, and serve as a control solution. According to the high performance liquid chromatography (General 0512) test, using bovine serum albumin bonded silica gel as filler, with N-propanol-phosphate buffer (pH 6.9) (0.71% anhydrous disodium hydrogen phosphate solution, add 0.69% sodium dihydrogen phosphate solution 600ml, shake, adjust pH 6.9 with 2mol/L sodium hydroxide solution)(8:92) as mobile phase, the detection wavelength is 302nm. Methotrexate was removed, and the mobile phase was dissolved and diluted to make a solution containing about 40ug per 1ml as a system-suitable solution. 20u1 injection liquid chromatograph, the peak order is (S)-methotrexate peak and (J) -methotrexate peak, the separation degree should be greater than 3.0. 2 ou1 of the test solution and the control solution were respectively injected into the liquid chromatograph, and the chromatograms were recorded. If (K) -methotrexate peak is present in the chromatogram of the test solution, the peak area shall not be greater than 3 times (3.0%) of the main peak area of the control solution.

Related substances

take this product, add mobile phase to dissolve and dilute to make a solution containing lmg per lml as a test solution; Take 1ml for precision measurement and put it in a 200ml measuring flask, dilute to the scale with the mobile phase, shake, and serve as a control solution. According to the chromatographic conditions under the content determination item, 50 u1 of the test solution and 50 u1 of the control solution are accurately measured and injected into the human liquid chromatograph respectively, and the chromatogram is recorded to 4 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the peak area of a single impurity shall not be greater than the main peak area of the control solution (0.5%), the sum of each impurity peak area shall not be greater than 4 times (2.0%) of the main peak area of the control solution.

moisture

take this product, according to the moisture determination method (General 0832 first method 1), the water content shall not exceed 12.0%.

ignition residue

take l.Og of this product and check it according to law (General rule 0841). The residue left shall not exceed 0.1%.

Heavy metals

take 0.5g of this product, add 25% magnesium sulfate sulfuric acid solution (take magnesium sulfate 25g, add 1 mol/ L sulfuric acid solution to dissolve) 4ml, shake, put on water bath and evaporate to dryness, at 800 ° C, it shall be slowly baked until it is completely charring, and the burning time shall not exceed 2 hours. It shall be allowed to cool and inspected according to law (General Principles 0821, second law), and the content of heavy metals shall not exceed 50 parts per million.

Last Update：2022-01-01 11:38:10

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Content determination

Authoritative Data Verified Data

measured by high performance liquid chromatography (General 0512).

chromatographic conditions and system suitability test

silica gel bonded with eighteen alkyl silane as filler; Acetonitrile-7.0% citric acid solution-2.0% anhydrous disodium hydrogen phosphate solution (8.5:10:80) (7.0% citric acid solution or 2.0% disodium hydrogen phosphate solution to adjust the pH value to 6.0) as the mobile phase; The detection wavelength was 302nm. Methotrexate and folic acid were taken, dissolved and diluted with the mobile phase to prepare about 0 per 1 ml. lmg mixed solution, take 10ul injection human liquid chromatograph, record chromatogram, the number of theoretical plate according to methotrexate peak calculation is not less than 1000, the separation degree of methotrexate peak and folic acid peak should be greater than 8.0.

assay

take this product, precision weighing, adding mobile phase dissolution and quantitative dilution to make a solution containing about 0.lm g per lml, take 10ul injection liquid chromatography with precision, record chromatogram; in addition, the methotrexate reference substance was determined by the same method, and the peak area was calculated by the external standard method.

Last Update：2022-01-01 11:38:11

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Category

Authoritative Data Verified Data

antineoplastic agents.

Last Update：2022-01-01 11:38:11

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Storage

Authoritative Data Verified Data

shade, seal, and store in a cool place.

Last Update：2022-01-01 11:38:11

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Methotrexate tablets

Authoritative Data Verified Data

This product contains methotrexate (C20H22N805) should be 95.0% to 110.0% of the label.

trait

This product is light orange and yellow.

identification

take an appropriate amount of the fine powder of this product, according to the identification (1) Test under the item of methotrexate, and show the same results.
in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.

examination

Related Substances: take an appropriate amount of this product's fine powder (about 10mg equivalent to methotrexate), place it in a 10ml measuring flask, add an appropriate amount of mobile phase, sonicate for 10 minutes, and let it cool, dilute to the scale with mobile phase, shake well, centrifuge, take the supernatant as the test solution; Take 1ml with precision, put it in a 200ml measuring flask, dilute to the scale with mobile phase, shake well, as a control solution. Tested according to the method under methotrexate related substances. If there are impurity peaks in the chromatogram of the test solution, the peak area of a single impurity shall not be more than 2 times (1.0%) the area of the main peak of the control solution, the sum of each impurity peak area shall not be greater than 6 times (3.0%) of the main peak area of the control solution.
Content uniformity 1 tablet of this product is placed in a 25ml measuring flask, and the content is determined according to the method under the content determination item, starting from "adding mobile phase 20ml", and the content is calculated according to the law, the provisions shall be met (General rule 0941).
dissolution dissolution of this product, according to the dissolution and release determination method (General 0931 second method), hydrochloric acid solution (9-1000)900ml as the dissolution medium, the rotation speed is 50 rpm, operate according to law, after 45 minutes, take the solution filtering, take the filtrate according to UV-visible spectrophotometry (General rule 0401), measure absorbance at the wavelength of 306nm; Take the appropriate amount of methotrexate control, precision weighing, dissolution and quantitative dilution of dissolution medium solution made of the same concentration, the same method to determine the absorbance, calculate the amount of dissolution of each tablet. The limit is 75% of the labeled amount and shall be in accordance with the provisions.
others shall be in accordance with the relevant provisions under the item of tablets (General rule 0101).

Content determination

Take 10 tablets of this product, precision weighing, fine grinding, precision weighing appropriate amount (about equivalent to methotrexate 2.5mg), put it in a 25ml measuring flask, add mobile phase 20ml, ultrasonic dissolution of methotrexate, cool, dilute to the scale with mobile phase, shake well, filter, take the filtrate as the test solution, according to the method under methotrexate content determination, take a sample of 10u1 and inject it into a liquid chromatograph, record the chromatogram; Take an appropriate amount of methotrexate reference substance, weigh it precisely, add the mobile phase to dissolve and quantitatively dilute it to about 0 per 1 ml. lmg solution, the same method of determination, according to the external standard method to calculate the peak area, that is.

specification

2.5mg

storage

light shielding, sealed storage.

Last Update：2022-01-01 11:38:12

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Methotrexate for injection

Authoritative Data Verified Data

This product is the sodium salt of methotrexate and sodium chloride appropriate sterile freeze-dried product. Based on the average loading, methotrexate (C20H22N805) should be 95.0% to 110.0% of the labeled amount.

trait

This product is yellow or brown loose blocks or powder.

identification

take this product, according to methotrexate under the identification of (1) test, showed the same results.
in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.

examination

alkalinity: take this product, add water to dissolve and dilute to make a solution containing about 2.5mg per lml, and measure it according to law (General rule 0631). The pH value should be 7.0~9.0.
clarity of solution take 1 bottle of this product, add 2ml of water (5mg specification or 0.lg specification) or 10ml (lg specification) to dissolve, the solution should be clear; If it is turbid, with 1 turbidity standard solution (5mg specification) or 2 Turbidity standard solution (0.lg specifications or lg specifications) (General Principles 0902 first method) shall not be more concentrated.
the contents under the item of difference in loading amount of related substances are taken, dissolved by adding mobile phase and diluted to prepare a solution containing 1 mg of methotrexate per 1ml for use as a test solution; 1ml for precision measurement, set in a 200ml measuring flask, dilute to the scale with the mobile phase, and shake to serve as a control solution. Tested according to the method under methotrexate related substances. If there are impurity peaks in the chromatogram of the test solution, the peak area of a single impurity shall not be more than 2 times (1.0%) the area of the main peak of the control solution, the sum of each impurity peak area shall not be greater than 6 times (3.0%) of the main peak area of the control solution.
weight loss on drying: take this product, use phosphorus pentoxide as desiccant, and dry under reduced pressure at 100°C to constant weight. The weight loss shall not exceed 5.0% (General rule 0831).
the content of this product (5mg specification bottle, the content is dissolved and transferred to a 50ml measuring flask with mobile phase, diluted to the scale with mobile phase, and shaken. According to the method under the content determination item, the content shall be measured and calculated according to law, and shall comply with the regulations (General rule 0941).
the bacterial endotoxin of this product is taken and checked according to law (General rule 1143). The amount of endotoxin in methotrexate per 1 mg should be less than 0. 20EU.
sterile take this product, dissolve and dilute with a suitable solvent to prepare a solution containing 1101 mg of methotrexate per lml, and treat it by membrane filtration method, and check it according to law (general rule).
others should comply with the relevant provisions under injection (General 0102).

determination of content

take the contents under the item of difference in loading, mix well, weigh an appropriate amount (about 10mg equivalent to methotrexate) precisely, add mobile phase to dissolve and quantitatively dilute to about 0% methotrexate per 1 ml. The solution of 1 mg was obtained as a test solution by measurement according to the method under the item of methotrexate content measurement. (5mg specification based on mean content uniformity)

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid Request for Quotation

Methotrexate

CAS: 59-05-2

Molecular Formula: C20H22N8O5

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Names and Identifiers

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Physico-chemical Properties

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Risk and Safety

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Reference

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Standard

Authoritative Data Verified Data

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Trait

Authoritative Data Verified Data

specific rotation

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Introduction

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Differential diagnosis

Authoritative Data Verified Data

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Exam

Authoritative Data Verified Data

(R)-methotrexate

Related substances

moisture

ignition residue

Heavy metals

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Content determination

Authoritative Data Verified Data

chromatographic conditions and system suitability test

assay

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Category

Authoritative Data Verified Data

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Storage

Authoritative Data Verified Data

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Methotrexate tablets

Authoritative Data Verified Data

trait

identification

examination

Content determination

category

specification

storage

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid - Methotrexate for injection

Authoritative Data Verified Data

trait

identification

examination

Supplier List

N-(P-(((2,4-Diamino-6-Pteridinyl)Methyl)Methylamino)Benzoyl)-L-Glutamic Acid